Related Experiment Video
Updated: Jul 15, 2025
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12.2K
Targeting estrogen receptor signaling for treating heart failure
Chenyue Qian1, Jingjin Liu2,3,4,5,6, Huadong Liu7,8,9,10,11
1The Second Clinical Medical College, Jinan University, Shenzhen, 518020, Guangdong, China.
Heart Failure Reviews
|October 2, 2023
Summary
Premenopausal women show lower heart failure (HF) rates due to estrogen
Area of Science:
- Cardiovascular Science
- Endocrinology
- Women's Health
Background:
- Heart failure (HF) is a global health concern.
- Premenopausal women exhibit lower HF incidence, morbidity, and mortality compared to postmenopausal women and men.
- Estrogen is believed to confer cardioprotection in premenopausal women, but mechanisms are not fully understood.
Purpose of the Study:
- To review the role of estrogen receptors in the cardiovascular system.
- To elucidate the mechanisms of estrogen's cardioprotective effects in heart failure.
- To explore potential therapeutic strategies targeting these mechanisms.
Main Methods:
- Literature review of studies on estrogen receptors in the cardiovascular system.
- Analysis of research on estrogen's impact on heart failure pathophysiology.
- Examination of clinical and preclinical data on hormone replacement therapy and exercise interventions.
Main Results:
- Estrogen receptors are present in cardiovascular tissues.
- Estrogen signaling pathways are implicated in mitigating heart failure progression.
- Hormone replacement therapy and exercise show potential in modulating these pathways.
Conclusions:
- Estrogen's cardioprotective effects in heart failure are mediated through specific receptor pathways.
- Targeting estrogen mechanisms offers promising avenues for HF prevention and treatment.
- Further research is warranted to optimize therapeutic interventions.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
01:29Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
412
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
412
01:22Heart Failure Drugs: β-Blockers
357
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
357